Takeuchi I, Kaburaki Y, Arai K, et al. - Researchers tested the safety and effectiveness of infliximab for very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed before 6 years of age. They retrospectively reviewed records of a cohort of children with VEO-IBD who had received infliximab in a Japanese tertiary children's hospital for their disease features and clinical course. For the descriptive comparison, study participants were classified into three groups: ulcerative colitis type (UCT), non-UCT with perianal disease (NUC-PD), and non-UCT without perianal disease (NUC-NPD). In conclusion, infliximab seemed to be useful for VEO-IBD children. With less infusion reaction, children with NUC-PD and NUC-NPD responded better than with UCT.